# PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/pi3k-akt-mtor-pathway-alterations-in-advanced-nsclc-patients-after-progression/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Wenfeng Fang,Yihua Huang,Weiguang Gu,Jiadi Gan,Wenjing Wang,Shiyue Zhang,K. Wang,Jianhua Zhan,Yunpeng Yang,Yan Huang,Hongyun Zhao,Li Zhang |
| Citations | 91 |
| DOI | 10.21037/tlcr-20-141 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | diamond |
| OA URL | https://tlcr.amegroups.com/article/viewFile/42164/pdf |
| OpenAlex ID | https://openalex.org/W3044772769 |
| PMID | 32953503 |
| Type | article |
| Year | 2020 |

## Paper authors

- [Yihua Huang](https://scholariq.org/researchers/yihua-huang/)

## Paper journal

- [Translational Lung Cancer Research](https://scholariq.org/journals/translational-lung-cancer-research/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.